Michael Makris/LinkedIn
Jan 19, 2026, 14:17
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.
The patients were receiving half the approved dose of the drug.
Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.
If you saw these data, you would not know that the patients were only using half the approved dose.
Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?
Roche will clearly never do such a study, it will need to be done independently.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis